Search the Newsreel

TradingKey

This article provides a detailed income statement for CO2 Energy Transition Corp (NOEM), covering quarterly and annual financial performance up to FY2026Q1. It includes key financial metrics such as operating expenses, operating profit, net non-operating interest income, income before tax, income tax, and various …

Insight Enterprises, Inc. Revenue Breakdown – SWB:IEI

Insight Enterprises, Inc. (IEI) generated €7.02 billion in revenue last year, primarily from its Hardware segment which contributed €3.94 billion. The United States was the company's largest regional contributor, accounting for €5.29 billion of the revenue.

Intensity Therapeutics Inc (INTS) Cash Flow

This article presents the cash flow statement for Intensity Therapeutics Inc (INTS), detailing its operating, investing, and financing cash flows on a quarterly and annual basis. It includes a table with financial figures exhibiting year-over-year changes for various cash flow components. The piece also …

Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Intensity Therapeutics Inc (INTS), evaluating its stock based on various indicators and moving averages. It categorizes signals from these tools as Buy, Sell, or Neutral, and offers a summary of the stock's current technical status. The analysis …

Insight Enterprises (NSIT) Following AI And Cloud Demand Narrative Faces A Valuation Test

Insight Enterprises (NSIT) stock has recently seen a 90-day surge but a 1-year decline, closing at $117.65. While a narrative fair value suggests it's overvalued at $107.50 due to its AI and cloud exposure, another view based on its P/E ratio of 19.8x suggests …

INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030

Intensity Therapeutics Inc. (INTS) closed at $4.45 with a 0.68% increase. The company, a late-stage clinical biotechnology firm, is developing treatments for cancer with its lead product candidate, INT230-6, currently in Phase 3 trials. Analysts rate the stock as a "Buy" with a target …

Insight Enterprises (NSIT) Stock Looks Cheap On Fair Value After A 40% Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Insight Enterprises stock has climbed 40.1% year to date, and with both its intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and …

NSIT|Insight Enterprises Inc|Price:117.650|Chg%:+1.990

This article provides a comprehensive stock analysis of Insight Enterprises Inc (NSIT) by TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status. The company, a global solutions integrator, has high institutional ownership and analysts generally rate it as a "Buy" with …

Insight Enterprises Inc (NSIT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Insight Enterprises Inc (NSIT), identifying its major institutional holders such as BlackRock, Vanguard, and Fidelity. It breaks down shareholder types by proportion, providing insights into the institutional ownership landscape. The report also includes historical institutional shareholding data …

Insight Enterprises Inc (NSIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Insight Enterprises Inc (NSIT), highlighting its current earnings forecast score of 7.50 and ranking within the Software & IT Services industry. It details analyst ratings, target prices, and expected future revenue and EPS, indicating a general "Buy" …

INTS Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Advances - Financial Data

3 Stocks That Might Be Trading Below Their Estimated Intrinsic Values

This article identifies three U.S. stocks—Insight Enterprises (NSIT), Ouster (OUST), and Prosperity Bancshares (PB)—that are trading below their estimated intrinsic values based on future cash flows. Despite various market conditions and challenges, all three companies show promising earnings growth forecasts and strategic initiatives that …

J.P. Morgan Maintains Insight Enterprises(NSIT.US) With Hold Rating, Raises Target Price to $135

J.P. Morgan has reiterated its Hold rating on Insight Enterprises (NSIT.US) and increased its price target to $135. This indicates a continued cautious but slightly more optimistic outlook on the company's stock from the analyst.

NSIT5813006 Bond Profile — Key Metrics

This article provides a detailed profile of the NSIT5813006 bond issued by Insight Enterprises, Inc. Key metrics such as the issue date, maturity date, outstanding amount, face value, and coupon rate are highlighted. The bond, maturing on May 15, 2032, has a 6.63% coupon …

NSIT5813006 Bond Risk Profile

This article provides a bond risk profile for NSIT5813006, an Insight Enterprises, Inc. bond with a 6.625% coupon maturing on May 15, 2032. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors make informed …

Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading

Intensity Therapeutics (INTS) director Donovan Daniel received a stock option grant for 5,500 shares of common stock on July 16, 2026. The option has an exercise price of $4.90 per share, expires on July 16, 2036, and vests in four equal annual installments beginning …

Will Insight Enterprises (NSIT) Beat Estimates Again in Its Next Earnings Report?

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Insight Enterprises (NSIT). This company, which is in the Zacks …

CO2 Energy Transition Shareholders Approve SPAC Extension Plan

ETM Finalises Acquisition of Spain’s Penouta Critical Minerals Mine

Intensity Therapeutics (INTS) Proxy filing Summary

Intensity Therapeutics (INTS) has released a proxy filing summary for its upcoming virtual annual meeting on June 16, 2026. Shareholders as of April 23, 2026, will vote on proposals including the election of two directors, ratification of the auditor, and amendments to equity plans. …

Co2 Energy Transition Corp - to Accept Redemp

The article states that Co2 Energy Transition Corp will accept relinquishment of a certain asset. No further details are provided in this document.

Intensity Therapeutics (INTS) Q1 2026 earnings summary

Intensity Therapeutics (INTS) reported a Q1 2026 net loss of $2.4 million, an improvement from Q1 2025, primarily due to reduced R&D expenses. The company ended the quarter with $10.2 million in cash, supported by recent fundraising and a new ATM facility, but faces …

CO2 Energy Transition Corp. Announces Shareholder Approval of SPAC Extension and Deadline for Acceptance of Redemption Reversals

Houston, TX, July 21, 2026 (GLOBE NEWSWIRE) -- CO2 Energy Transition Corp. (Nasdaq: NOEM) today announced that shareholders have approved all of the proposals that were considered at the shareholder meeting that took place today including a proposal to extend the deadline by which …

Insight Enterprises Inc. (IEI) Q3 2024 Earnings Report - Results, Call & Slides

Insight Enterprises Inc. (IEI) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company recorded an actual EPS of €1.92 against a consensus of €2.02, and actual revenue of €1.83B compared to an expected €1.96B, marking a year-over-year revenue decline of …

Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90

Intensity Therapeutics, Inc. (INTS) director Emer Leahy was granted 5,500 stock options at an exercise price of $4.90 per share. These options will vest in four equal annual installments starting July 16, 2026, and will expire on July 16, 2036. This transaction reflects equity …

Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90

Intensity Therapeutics has granted its Chief Financial Officer, Joseph Talamo, 34,000 stock options with an exercise price of $4.90 per share. These options, which expire on July 16, 2036, will vest in four equal annual installments starting July 16, 2027, contingent on his continued …

Press Release: Insight Enterprises, Inc. to Report Second Quarter 2026 Financial Results on August 6, 2026

Insight Enterprises, Inc. (NASDAQ: NSIT) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026. The company will also host a conference call and live webcast to discuss these results.

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Intensity Therapeutics has restarted patient treatment in its Phase 2 INVINCIBLE-4 Study for triple-negative breast cancer (TNBC) in Switzerland, after a temporary pause to address skin irritation issues. The trial, using INT230-6 before standard-of-care immunotherapy-chemotherapy, aims to improve pathological complete response rates in patients …

Insight Enterprises Inc (NSIT) Stock Price & 30 Year Financial Data

This article provides comprehensive financial data for Insight Enterprises Inc (NSIT), including its current stock price, market capitalization, and various financial ratios like P/E and P/B. It also details growth rates for revenue, EPS, EBIT, EBITDA, and free cash flow over 1-year, 5-year, and …

CO2 Energy Transition Corp. (NOEM) Stock: Signs LOI to Recover Lithium, Strontium From Texas Oilfield Brine

Price to earnings forward of CO2 Energy Transition Corp. – NASDAQ:NOEMU

The article focuses on the "Price to earnings forward" metric for CO2 Energy Transition Corp. (NASDAQ: NOEMU). It presents a financial data point for the company within the TradingView platform, indicating market closure and no trades for the specified period.

Insight Enterprises schedules before-market results and 9 a.m. call

Insight Enterprises, Inc. (Nasdaq: NSIT) announced it will release its second-quarter 2026 financial results prior to market open on August 6, 2026. The company will also host a conference call and live webcast at 9:00 a.m. ET on the same day to discuss the …

Energy Transition Minerals (ASX: ETM) Shares Decline as Critical Minerals Outlook Remains in Focus

Intensity Therapeutics (INTS) AGM 2026 Summary

The Intensity Therapeutics (INTS) 2026 Annual General Meeting (AGM) was held virtually on June 16, 2026, at 10:30 AM ET. Key proposals included the re-election of two directors, ratification of EisnerAmper LLP as auditors, and amendments to the 2021 Stock Incentive Plan and 2024 …

Intensity Therapeutics (INTS) Q4 2025 earnings summary

Intensity Therapeutics (INTS) reported its Q4 2025 earnings, highlighting a cash balance of $11.9 million at year-end, providing a cash runway into Q2 2027. The company raised over $20 million in gross proceeds in 2025 and saw reduced R&D and G&A expenses, leading to …

Intensity Therapeutics resumes patient dosing in Swiss trial

Intensity Therapeutics Inc. has resumed patient dosing in its INVINCIBLE-4 Study in Switzerland for early-stage, operable triple-negative breast cancer, following a temporary pause due to skin irritation. The company's stock has faced volatility, but analysts maintain a bullish outlook, with InvestingPro suggesting it is …